An NCI-designated Comprehensive Cancer Center
Breakthroughs - CMV vaccine - 256x256
Scientist working on novel, DNA-based approach to COVID-19 vaccine
May 21, 2020 | by Wayne Lewis
City of Hope's Larry W. Kwak, M.D., Ph.D., is building on a vaccine he pioneered for the treatment of lymphoma. The DNA-based delivery system has already been allowed by the FDA, which could shave about a year off of development time.
Research | COVID-19 | Patient Care
Ajay Goel
New test detects pancreatic cancer spread to lymph nodes
May 20, 2020 | by Zen Vuong
Being able to detect lymph node spread, currently a technological challenge, would change the treatment paradigm for pancreatic cancer patients, reducing unnecessary surgeries. The technique involves using genomics to search for a novel microRNA biomarker that indicates lymph node metastasis.
Research | Patient Care
Antibody | City of Hope
COVID-19: A guide to vaccines, antibodies and antivirals
May 18, 2020 | by Abe Rosenberg
Vaccines, antiviral drugs and antibody tests are among the weapons being used to fight the COVID-19 virus. Each works in a different way. Here’s a short guide.
COVID-19 | Research
stem cells
Special coronavirus concerns for bone marrow transplant patients
May 18, 2020 | by Maxine Nunes
Few are as vulnerable to COVID-19 as bone marrow transplant (BMT) patients. How is City of Hope protecting BMT patients within the hospital, and how can they stay safe once they return home?
Patient Care | COVID-19
Teachers Study
City of Hope researchers mining database for COVID clues
May 12, 2020 | by Zen Vuong
Researchers looking to control the spread of COVID-19 are working with City of Hope scientists who manage a 25-year-old landmark study originally developed to track breast cancer. By using the database, they can look at where the novel coronavirus is spreading, who it’s affecting and their health outcomes.
Research | COVID-19
pancreatic cancer
City of Hope develops tests to categorize pancreatic cancer risk
May 8, 2020 | by Katie Neith
Researchers led by Ajay Goel, Ph.D., M.S., have developed two new tests for assessing risk levels in people with pancreatic ductal adenocarcinoma, or PDAC. Such tests could lead to better personalized care for these patients and, therefore, potentially improved outcomes.
Patient Care | Research